Acute Coronary Syndrom - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

文章摘要

Epidemiology and Clinical Outcomes of Patients With Inflammatory Bowel Disease Presenting With Acute Coronary Syndrome
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome
Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative
Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients
Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study
Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association
Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Association of Plaque Location and Vessel Geometry Determined by Coronary Computed Tomographic Angiography With Future Acute Coronary Syndrome–Causing Culprit Lesions
Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?

Clinical Trial

2017 Aug;47(1):133-142.

JOURNAL：Semin Arthritis Rheum.

Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study

Sparks JA, Barbhaiya M, Karlson EW et al.

4371

Keywords: Genetics; Methotrexate; Pharmacovigilance; Polyglutamate; Toxicity

FULL TEXT PDF